Study study type PathologyT1T0Patientssample sizesROB Results

mBC-Triple negative (TNBC) - 2nd Line (L2) breast cancer - triple negative mBC-Triple negative (TNBC) - 2nd Line (L2)

versus Standard of Care (SoC)
sacituzumab govitecan
ASCENT (all population), 2021
  NCT02574455
RCTmBC-Triple negative (TNBC) - 2nd Line (L2)Sacituzumab govitecansingle agent chemotheraopy of the physician's choice (eribulin, vinorelbine, capecitabine or gemcitabine)Patients with metastatic triple-negative breast cancer that was relapsed or refractory to two or more previous standard chemotherapy regimens for unresectable, locally andvanced or metastatic disease (previous thearapy had to include taxanes).267 / 262NA
suggested
  • suggested 49 % decrease in deaths (OS) (PE)
  • suggested 57 % decrease in progression or deaths (PFS) (PE)
ASCENT (patients without brain metastases), 2021
  NCT02574455
RCTmBC-Triple negative (TNBC) - 2nd Line (L2)Sacituzumab govitecansingle agent chemotheraopy² of the physician's choice (eribulin, vinorelbine, capecitabine or gemcitabine)Patients with metastatic triple-negative breast cancer that was relapsed or refractory to two or more previous standard chemotherapy regimens for unresectable, locally andvanced or metastatic disease (previous thearapy had to include taxanes).235 / 233NA
suggested
  • suggested 52 % decrease in deaths (OS) (PE)
  • suggested 59 % decrease in progression or deaths (PFS) (PE)